Back to results
US 12,686,711 B2Granted
DARIC interleukin receptors
AssigneeRegeneron Pharmaceuticals, Inc.
InventorWai-Hang Leung
Life of this patent
Estimating the term…
Abstract
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Claims14
A polynucleotide encoding a fusion polypeptide, wherein the fusion polypeptide comprises:
- (a) a first polypeptide comprising, in the following order:
- (i) a first extracellular multimerization domain;
- (ii) a first transmembrane domain;
- and
- (iii) an IL-18R1 immune receptor intracellular signaling domain;
- (b) a polypeptide cleavage signal;
- and
- (c) a second polypeptide comprising, in the following order:
- (i) a second extracellular multimerization domain;
- (ii) a second transmembrane domain;
- and
- (iii) an IL-18RAP immune receptor intracellular signaling domain;
- wherein the first extracellular multimerization domain comprises an FKBP12-rapamycin binding (FRB) polypeptide and the second extracellular multimerization domain comprises an FK506 binding protein (FKBP12) polypeptide;
- or
- wherein the first extracellular multimerization domain comprises an FKBP12 polypeptide and the second extracellular multimerization domain comprises an FRB polypeptide;
- and
- wherein the fusion polypeptide has a sequence having at least 95% identity to SEQ ID NO:
- 5.
15 more elements
A polynucleotide encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.